logo
After record-breaking Everest climbers revealed they use hypoxic tents to get altitude ready without acclimatizing on the mountain, we look at how the technology works

After record-breaking Everest climbers revealed they use hypoxic tents to get altitude ready without acclimatizing on the mountain, we look at how the technology works

Yahoo03-06-2025
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Around 800 people attempt to climb Mount Everest each year, braving extreme conditions for the chance to say they've stood on top of the world.
Along with rigorous physical and mental training, hopefuls need to prepare for the harrowing effects of altitude atop Earth's tallest mountain, where the amount of oxygen taken in with each breath is drastically lower than at sea level.
Traditionally, climbers have acclimatized by spending significant time in the mountains, heading up and down to prepare their bodies for the dizzying heights, and reducing the impact of altitude sickness. This tried and tested method has proven effective for the past 70 years of Everest expeditions, but comes with one major drawback: time.
Without four to six weeks to dedicate to acclimatization, many Everest hopefuls are now turning to modern technology to help them prepare, sleeping and exercising in specialist acclimatizing 'hypoxic' tents, which do away with the need to spend months in the mountains.
'You sleep like garbage if you're not acclimatized, you lose your appetite, so you wither away
Brian Oestrike, CEO of Hypoxico Altitude Training Systems
As alien as it may sound, hypoxic tents, otherwise known as altitude tents, have become increasingly common in recent years, used by alpinists and climbers to prepare for harsh conditions.
This year, a group of British veterans in their forties and fifties used hypoxic tents in combination with controversial Xenon gas to speed-climb the mountain, summiting a record four days after arriving in Nepal and effectively going from sea level in London, to the highest peak on the planet in 5 days.
The very next day, US-Ukrainian climber Andrew Ushakov claimed to have broken their record, after spending over 400 hours acclimatizing in a hypoxic tent. Ushakov says he went from New York to the Everest summit in just 3 days, 23 hours, and 27 minutes.
So what are hypoxic tents, and how can they help climbers achieve these once-unthinkable feats? Read on for everything you need to know.
Put simply, hypoxic tents mimic the low oxygen levels of high-altitude environments.
The air at sea level contains 20.9% accessible oxygen, a number that drops dramatically the higher you get. At Everest base camp, it falls to around 10.4%. By the summit, it's down to just a third of the accessible oxygen quotient at regular sea-level.
In healthy individuals, blood oxygen saturation levels sit around 98% to 100% at sea level. At altitude, that number drops to roughly 87% to 92% This has a weakening effect and can cause altitude sickness.
Hypoxic tents simulate this mix with a generator or pump, which removes oxygen and replaces it with nitrogen, reducing the amount of oxygen in the air to high-altitude levels.
Sleeping in the simulated altitude conditions of a hypoxic tent triggers your body to saturate your blood oxygen levels, releasing red blood cells and ready your system for conditions at 20,000ft (6,096m).
'As you expose yourself to altitude, your kidneys release EPO [erythropoietin], which starts this physiological change that leads to an increase in red blood cells, but more so into a better ability to transport and utilize oxygen,' Brian Oestrike, CEO of Hypoxico Altitude Training Systems tells us.
Climbers like Ushakov use hypoxic tents to ready themselves for the unforgiving mountain conditions atop the globe's tallest peaks. Saturating your blood oxygen levels can be beneficial in several ways, reducing the risk of altitude sickness and preparing your body for the tiring effects of altitude.
'You improve your comfort and safety margin as you're ascending up through the mountains,' Oestrike explains. 'You sleep like garbage if you're not acclimatized, you lose your appetite, so you wither away as those things happen. By acclimatizing beforehand and using this equipment, you can offset your expedition, it improves your safety and your comfort margin.'
By mimicking arduous alpine conditions, hypoxic tents can reduce the time it takes to acclimatize.
'Most people, if they're going to the Himalayas, historically have a six to eight-week expedition itinerary,' continues Oestrike. 'It takes that long for your body to slowly adapt and build the red blood cells that carry oxygen and allow you to climb safely."
Ultra-running superstar Kilian Jornet slept inside a hypoxic tent for eight weeks before his maiden ascent of Mount Everest, mimicking altitudes of 13,000ft (3,962m) to 16,000ft (4,877m) without leaving sea level.
He then became the fastest man to climb Everest alone and without oxygen, summiting the 29,000ft (8,850m) behemoth in just 26 hours.
Although they're becoming increasingly popular with climbers and other extreme athletes, hypoxic tents do have their limitations and experts say they cannot be trusted as the sole method for acclimatization.
"It's not the full acclimatization. I would say it's the first step," says Grégoire Millet, Professor of Exercise Physiology at the Institute of Sport Sciences in Lausanne, France.
He explains that, even after months of sleeping in a hypoxic tent, "you will use some acclimatization, but not the full spectrum. You can be fully acclimatized in the tent, and not acclimatized to the real mountain".
In other words, hypoxic tents cannot fully prepare the body for the rigours and difficulties of climbing at very high altitudes. In the Himalayas, elite climbers (and paying clients) on expeditions aiming for the highest peaks enter what is known as the Death Zone, an extremely dangerous zone above 26,247ft (8,000m), where besides having to deal with temperatures potentially tumbling to -31°F (-35°C) and highly technical terrain, the oxygen in the air is so low it's impossible for humans to survive for long.
"You have to go to the real mountain for at least a few days before you travel," advises Millet, an expert in acclimatization technology.
He advises climbers to use the tents in combination with traditional acclimatization methods, like sleeping atop smaller mountains, before tackling any major peaks.
"It's better to use the tents, and then before you go to the Himalayas, it's recommended that you go for at least a few days to the Alps," he says.
He says your body acclimatizes differently at real altitude and, despite their many benefits, hypoxic tents cannot fully replicate the tough conditions and and lack of oxygen in the mountains.
It's not just mountaineers who put hypoxic tents to good use. All manner of sports people, from swimmers to footballers, use simulated altitude environments to expand their physical capabilities and access the benefits of altitude training.
'If you can transport and utilize oxygen better, that leads to better performance benefits, and literally just more ability to consume oxygen,' says Oestrike.
"Most of the elite athletes, they have a hypoxic chamber at home," adds Millet.
"It's not a tent, but it's a real chamber. It's the same idea, you decrease the oxygen concentration in the room."
By training and sleeping at altitude, athletes can increase what's known as their hemoglobin mass, which boosts the amount of oxygen they can utilize during exercise.
As Millet explains, this requires considerably more time than mountain acclimatization: "Every 100 hours sleeping in the tent, you will increase your hemoglobin by one percent."
Every member of the US Olympic rowing quad who won gold at the Paris 2024 games reportedly slept in hypoxic tents for six weeks before racing.
Although they're designed for elite athletes, hypoxic tents can be useful to outdoor enthusiasts of all abilities, helping to build fitness and intensify workouts.
When it comes to climbing, Oestrike suggests that hypoxic tents are even more useful to amateurs than professionals.
'Most people who are committed to an 8,000m (26,247ft) peak know what they're getting into, they know what the training looks like, and they know what it takes to prepare.
'High-level athletes are already training super intensively. So the person that's more modest and maybe needs to lose a little weight, they're going to see a greater upside.'
Of course, hypoxic tents are not required for easy-to-medium-difficulty ascents. Nor are they absolutely essential to climb giants like Mount Everest. Traditional, slower, acclimatization has proven itself as an effective, stress-tested method of alpine preparation.
Rather, hypoxic tents are an additional and convenient method of acclimatizing, to be used along with high-altitude climbing and intensive training.
You can read our exclusive interview with Andrew Ushakov here.
For more on climbing preparation, check out our expert guide.
The best ice axes: for tackling frozen terrain
The best climbing shoes: get a grip both indoors and out
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

High Lp(a) Signals Risk Beyond The Coronaries
High Lp(a) Signals Risk Beyond The Coronaries

Medscape

timean hour ago

  • Medscape

High Lp(a) Signals Risk Beyond The Coronaries

TOPLINE: Elevated levels of lipoprotein(a) [Lp(a)] were associated with significantly increased risks for incident peripheral artery disease and carotid artery stenosis. Among patients with peripheral artery disease, those with high levels of Lp(a) (≥ 150 nmol/L) had a high risk of progressing to major adverse limb events. METHODOLOGY: Despite lifestyle interventions and therapies for lowering levels of cholesterol, a residual risk for major atherosclerotic complication persists. Researchers analyzed data from a large prospective biobank (2006-2010) to investigate whether baseline levels of Lp(a) predict the risk for onset and progression of extracoronary athero­sclerotic vascular disease — a combination of peripheral artery disease and carotid artery stenosis. The UK biobank data included 460,544 individuals (average age at enrollment, 57 years; 54.2% men; 94.9% European) and followed them for a median duration of 13.6 years. Data on baseline serum levels of Lp(a) were retrieved, with levels ≥ 150 nmol/L (about 70 mg/dL) defined as high. The analysis assessed the incidence of peripheral artery disease and carotid artery stenosis and the progression to both the first major adverse limb event and first stroke. TAKEAWAY: Individuals with high levels of Lp(a) were older and more often men than those with normal levels of Lp(a) (P < .001 for both). Each 75-nmol/L (35 mg/dL) increase in levels of Lp(a) was associated with a 1.18-fold elevated risk for incident peripheral artery disease and a 1.17-fold increased risk for incident carotid artery stenosis (P < .0001 for both). Among patients with peripheral artery disease, those with high levels of Lp(a) had a 1.6-fold higher risk of developing major adverse limb events than those with normal levels of Lp(a) (P = .004). IN PRACTICE: 'Participants with established atherosclerotic vascular disease and elevated Lp(a) concentrations may represent the ideal group to benefit from targeted preventive interventions,' the researchers noted. '[The study's] findings make a strong case to explore the effect of therapies to lower Lp(a) in participants with PAD [peripheral artery disease] and carotid stenosis towards the goal of slowing disease progression and reducing major complications of amputation and stroke,' they added. SOURCE: This study was led by Tiffany R. Bellomo, MD, of Broad Institute of Harvard and MIT, Cambridge, Massachusetts. It was published online on July 28, 2025, in Circulation. LIMITATIONS: Measuring Lp(a) using immunoassays may be inaccurate for individuals with large Lp(a) isoforms. This study lacked measurement of ankle-brachial index to define peripheral arterial disease. The analysis may not have accounted for all potential confounding factors. DISCLOSURES: This study received grants from the National Heart, Lung, and Blood Institute and the National Human Genome Research Institute. One author reported receiving research grants and personal fees from several pharmaceutical and healthcare companies and holding equity in multiple healthcare data and biotech firms. The same author reported spousal employment at a pharmaceutical company. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

GPP Linked to Greater Healthcare Burden
GPP Linked to Greater Healthcare Burden

Medscape

time2 hours ago

  • Medscape

GPP Linked to Greater Healthcare Burden

TOPLINE: A retrospective US claims study found that adults with generalized pustular psoriasis (GPP) had significantly higher healthcare visits and costs than patients with plaque psoriasis alone. METHODOLOGY: Researchers conducted a retrospective analysis of 633 adults with GPP between 2016 and 2019 in a US claims database, of whom 344 had comorbid plaque psoriasis and 289 had GPP alone. They also assessed an equal number of 633 matched patients with plaque psoriasis. Nearly 70% of the patients were women, 58.1% were aged 45-54 years, and 64.8% had commercial insurance. The median follow-up time ranged from 2.5 to 2.9 years. Study outcomes were healthcare utilization and costs. TAKEAWAY: Patients with GPP demonstrated significantly higher median total visits than those with psoriasis alone (3 or 4 vs 2; P < .001), as well as increased outpatient/office visits (3 vs 2; P < .001) and laboratory use (2 vs 1; P < .05). Only patients with GPP had inpatient visits (34 patients) and ICU visits (1 patient); 12 patients with GPP vs 1 patient with psoriasis had emergency room visits only. Median total healthcare costs were $189 for all patients with GPP, $174 for those with GPP only, and $205 for those with GPP and psoriasis compared with $103 for those with psoriasis only (P < .001). Median outpatient/office costs were also higher for all patients with GPP ($180), those with GPP only ($168), and those with both GPP and psoriasis ($198) compared with those with psoriasis ($100; P < .001). Emergency room costs ranged from $58 to $1490 for 12 patients with GPP compared with $160 for 1 patient with plaque psoriasis. IN PRACTICE: The greater costs for healthcare resource utilization 'and associated costs for GPP versus plaque psoriasis underscore the need for improved long-term management of GPP,' the study authors wrote. Studies should evaluate the impact of new treatments on utilization of healthcare resources related to GPP, they added, noting that patients with GPP 'traditionally receive medications intended for plaque psoriasis, which lack evidence of effectiveness for GPP.' SOURCE: The study was led by Mark Lebwohl, MD, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, and was published online on July 24 in the Journal of the American Academy of Dermatology. LIMITATIONS: Possible miscoding in the claims database was a limitation, and the study period predated the FDA approval of spesolimab for treating GPP. DISCLOSURES: The study was funded by Boehringer Ingelheim. Lebwohl and two other authors disclosed receiving research funds, honoraria, and consulting fees from multiple pharmaceutical companies including AbbVie, Amgen, Arcutis, Avotres, and Boehringer Ingelheim. One author also reported receiving stock options from Connect Biopharma and Mindera Health and being editor in chief of the Journal of Psoriasis and Psoriatic Arthritis. Three authors are Boehringer Ingelheim employees. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Liver Cancer Risk Doubled in Men vs Women With Cirrhosis
Liver Cancer Risk Doubled in Men vs Women With Cirrhosis

Medscape

time2 hours ago

  • Medscape

Liver Cancer Risk Doubled in Men vs Women With Cirrhosis

TOPLINE: Men with cirrhosis had higher risks for adverse liver events than women, including more than twice the risk for hepatocellular carcinoma. This sex-based risk disparity was more pronounced in nonviral cirrhosis, especially alcohol-related liver disease. METHODOLOGY: Although women typically experience less-severe early-stage chronic liver disease, sex-based differences in advanced stages remain unclear. This retrospective study explored the association between sex and the risk for adverse liver events in propensity score-matched pairs of women and men with cirrhosis, using a US insurance claims database with up to 10 years follow-up. Primary outcomes were the incidence of decompensated cirrhosis, hepatocellular carcinoma, and liver transplant, with events defined as those occurring 6 months after initial cirrhosis diagnosis. Subgroup analyses were performed by major liver disease etiologies: hepatitis B virus, hepatitis C virus, alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease (MASLD), and others. TAKEAWAY: Researchers included 169,711 women (mean age, 58.1 years) and an identical number of men (mean age, 57.7 years). Compared with women, men with cirrhosis had significantly higher risks for decompensated cirrhosis (hazard ratio [HR], 1.16; P < .001), hepatocellular carcinoma (HR, 2.10; P < .001), and liver transplant (HR, 1.63; P < .001). By liver etiology, the greatest disparities occurred in alcohol-related disease, where men had higher risks for decompensated cirrhosis (HR, 1.13; P < .001), hepatocellular carcinoma (HR, 2.40; P < .001), and liver transplant (HR, 1.36; P < .001); this was followed by MASLD and hepatitis C virus infection. In patients with hepatitis B, sex differences were significant only for hepatocellular carcinoma, with men at a higher risk (HR, 1.60; P = .02). IN PRACTICE: 'If differences in disease severity at presentation emerge, efforts to improve early detection and linkage to cirrhosis care should be prioritized. These methods can include the implementation of informatics-based tools to surveil available clinical data (eg, automated fibrosis-4 calculation, steatosis identification on imaging) within the electronic health record to identify patients at risk for advanced chronic liver disease, link them to specialty care, and initiate guideline-recommended surveillance,' experts wrote in an accompanying editorial. SOURCE: This study was led by Yu Shi, MD, PhD, Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California. It was published online in JAMA Network Open. LIMITATIONS: This study relied on standardized diagnostic codes to identify cirrhosis complications, which may have introduced misclassification. Results may not be generalizable to uninsured populations, who potentially have more severe disease. The lack of laboratory data prevented the calculation of Model for End-Stage Liver Disease with sodium levels and Child-Pugh scores for the assessment of disease severity. DISCLOSURES: The Stanford Center for Population Health Sciences Data Core, which provided data for this study, was supported by the National Institutes of Health's National Center for Advancing Translational Sciences Clinical and Translational Science Award, as well as internal funding from Stanford University. One author reported receiving grants and personal fees from various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store